Patient recruitment began July 24 for this nationwide trial that will explore whether targeted therapies can be effective for children and adolescents with solid tumors that harbor specific genetic mutations and have progressed during or after standard therapy.
New results from a large international clinical trial suggest a conservative approach to lymph node removal surgery may be best for people with melanoma that has spread to one or a small number of nearby lymph nodes.
A pair of phase 2 clinical trials support the Food and Drug Administration’s approval of dabrafenib (Tafinlar®) and trametinib (Mekinist®) in combination for the treatment of metastatic non-small cell lung cancer (NSCLC) that has an alteration in the BRAF gene called the V600E mutation.
This phase 2 trial studies how well pembrolizumab works in treating patients with medullary thyroid cancer that has come back or spread to other places in the body.
This phase 1 trial studies the side effects and best dose of veliparib when given together with liposomal irinotecan in treating patients with solid tumors.
This phase 1/2 trial studies the side effects and best dose of anetumab ravtansine and to see how well it works in treating patients with mesothelin expressing stage IIIB-IV lung cancer that cannot be removed by surgery.
